|Bid||2.0500 x 0|
|Ask||2.0700 x 0|
|Day's Range||2.0300 - 2.1000|
|52 Week Range||1.4500 - 3.8300|
|Beta (5Y Monthly)||2.07|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 26, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
The big shareholder groups in Race Oncology Limited ( ASX:RAC ) have power over the company. Insiders often own a large...
Australian biotech and precision oncology company, Race Oncology, has announced breakthrough preclinical research that has found its drug Zantrene® is able to protect heart muscle cells from death while improving the killing of breast cancer cells when used in combination with the anthracycline, doxorubicin.